×
About 298 results

ALLMedicine™ Prostate-specific Antigen Testing Center

Research & Reviews  97 results

Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting ...
https://doi.org/10.1001/jamaoncol.2021.5129
JAMA Oncology; Hamdy FC

Nov 12th, 2021 - Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through?|2021|Hamdy FC,|

Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Serv...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587214
JAMA Oncology; Leapman MS, Wang R et. al.

Nov 12th, 2021 - In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing ...

Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy fo...
https://doi.org/10.1016/j.eururo.2021.07.024
European Urology; Van Poppel H, Roobol MJ et. al.

Aug 20th, 2021 - Recommendations against prostate-specific antigen (PSA) testing in 2012 have increased advanced-stage diagnosis and prostate cancer-specific mortality rates. To present the position of the European Association of Urology (EAU) in 2021 and provide ...

Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis ...
https://doi.org/10.1016/j.euf.2021.07.009
European Urology Focus; Leong JY, Pinkhasov R et. al.

Aug 2nd, 2021 - Patients with disabilities represent a unique minority population. The incidence of prostate-specific antigen (PSA) testing among this population is unknown. To compare PSA testing rates and associated predictors among men with and without reporte...

Nonlinear Relationship Between Age and Likelihood of Undergoing Prostate-Specific Antig...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246524
American Journal of Men's Health; He H, Liu T et. al.

Jun 26th, 2021 - To investigate the nonlinear relationship between age and the likelihood of undergoing prostate-specific antigen (PSA) testing, and the difference of factors influencing the test likelihood among subjects aged 40-54, 55-69, and ≥70 years. Data wer...

see more →

News  22 results

The Cost of More Surveillance Scanning: Patients' Mental Health
https://www.medscape.com/viewarticle/952906

Jun 17th, 2021 - I was in the middle of a clinic visit when one of our nurses knocked on my door. "I'm sorry to interrupt, but your patient's wife just called and really wants to know what his scan showed. " The patient was a man with metastatic lung cancer Like d...

Has COVID-19 Led to More Advanced Cancers?
https://www.medscape.com/viewarticle/948278

Mar 29th, 2021 - Months of lockdowns throughout 2020 brought mass cancer screening programs to a halt in the United States. Early in the COVID-19 pandemic, the American Cancer Society recommended that "no one should go to a health care facility for routine cancer ...

Dutasteride May Slow Prostate Cancer Progression
https://www.onclive.com/view/dutasteride-may-slow-prostate-cancer-progression

Dec 5th, 2020 - Neil Fleshner, MD Dutasteride, a 5α-reductase inhibitor approved for the treatment of benign prostatic hyperplasia, may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy, as wel...

IPCC Conference to Focus on Issues Facing Clinicians
https://www.onclive.com/view/ipcc-conference-to-focus-on-issues-facing-clinicians

Dec 5th, 2020 - Leonard G. Gomella, MD During the past year, changes in the diagnosis and treatment of prostate cancer have sparked increased discussion and debate, with many patients and their treating physicians left wondering how to proceed appropriately. ...

Dr. Morris on Challenges of Radium-223 Treatment in Prostate Cancer
https://www.onclive.com/view/dr-morris-on-challenges-of-radium223-treatment-in-prostate-cancer

Nov 13th, 2020 - Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer. In a phase I/IIa clinical trial evaluating the effects of radium-223 with docetaxel versus docetaxel ...

see more →